A team from the University of Virginia and Virginia Commonwealth University reports that Niemann-Pick disease type C (NPC), a rare inherited disorder of lysosomal cholesterol handling, is not just a lipid-storage problem. Using mutant mice and patient cells, they show it also triggers widespread DNA breakage, chronic innate-immune (STING) activation, mitochondrial trouble, and a molecular signature of accelerated aging. They then repurpose fingolimod, an FDA-approved multiple sclerosis pill, and find it partly reverses these features, calms brain inflammation, and, most strikingly, extends lifespan in worms and in aged male mice. The work is preliminary, but it positions fingolimod as a candidate geroprotector worth watching.
For decades, Niemann-Pick disease type C has been filed under “lipid storage disorder,” a tragic childhood illness in which cholesterol gets trapped inside the cell’s recycling compartment, the lysosome. This new preprint argues that description is too small. When the NPC1 gene fails, the researchers show, the damage radiates outward into some of the same machinery that breaks down in normal aging.
The team looked in two directions at once. In mice engineered with the most common human NPC mutation, loss of NPC1 produced the expected motor problems and loss of Purkinje neurons in the cerebellum, alongside inflamed microglia and astrocytes. But it also produced something not previously mapped in this disease: extensive DNA double-strand breaks in the brain. In cells taken from an NPC patient, the picture was similar, with breaks concentrated at gene switches and at unusual four-stranded DNA structures called G-quadruplexes. Loose fragments of mitochondrial DNA were seen drifting outside the mitochondria, exactly the kind of stray genetic material that trips the cell’s viral-alarm system, cGAS-STING, and drives chronic inflammation.
The big idea is that a single broken lysosome sets off a cascade that looks a lot like aging in fast-forward. A transcriptomic “aging clock” applied to the patient cells scored them as dramatically older than healthy controls.
Then comes the twist that will interest the longevity field. Fingolimod, sold as Gilenya for multiple sclerosis, is a sphingosine-1-phosphate receptor modulator that dampens immune activity. Given to the NPC mice and cells, it improved cholesterol clearance, raised the lysosomal protein LAMP1, quieted STING signaling, normalized mitochondrial membrane potential, reduced the senescence marker p21, and pushed the aging-clock score back toward youth. It did not fix the underlying DNA damage, an important limit the authors are candid about.
The headline claim reaches beyond the disease. In healthy nematode worms, fingolimod extended median lifespan by roughly 30 percent. In genetically normal aged mice, it extended median lifespan by about 7 percent, but only in males. That cross-species pattern places fingolimod, tentatively, in the same conversation as rapamycin, metformin, and acarbose. The evidence is early, the effect modest, and the biology sex-specific, but the direction of travel is intriguing.
Actionable Insights
The honest take-home is that this is not yet a protocol you can act on, and the effect sizes explain why. In genetically normal aged mice, fingolimod raised median lifespan from 657 to 701 days, an increase of 44 days, or about 6.7 percent, and only in males; females showed 698 versus 705 days (roughly 1 percent, not significant). In worms, median lifespan rose from 15 to 19 days, about 27 percent. The cellular aging-clock score improved by roughly half (a 51 percent reversal of the disease-associated acceleration), and abnormal mitochondrial DNA copy number, elevated about three-fold, was partly corrected.
Put in perspective, a 7 percent median gain in one sex is modest, much smaller than what rapamycin produces, and was measured against short-lived control animals, which tends to inflate apparent benefit. Fingolimod is prescription-only, an immunosuppressant, and carries real risks including slowed heart rate, macular edema, elevated liver enzymes, lymphopenia, and infection. There is no human longevity data. The defensible action for now is awareness, not self-experimentation: track this drug class, and note that lysosomal health, inflammation control, and mitochondrial maintenance are the levers it appears to pull.
Context and Source
- Open access paper: NPC1 deficiency engages a lysosome-genome-immune program linked to neurodegeneration and cellular aging signatures.
- Authors and institutions: Abyadeh, Zarei Kheirabadi, Hou, and colleagues, corresponding author Alaattin Kaya. Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, and the School of Medicine and School of Life Sciences at Virginia Commonwealth University.
- Country: United States.
- Journal and impact evaluation: This is a preprint. It has not been peer reviewed and has not been published in any journal,